Generics and biosimilars saved patients with cancer $16.0 billion in 2020, and savings for the past 10 years total $106.5 billion. An estimated 1.8 million new cases of cancer are diagnosed in the United States each year, and more than 600,000 people die annually from the disease, according to the National Cancer Institute. Patients rely on biosimilar medications to treat breast, stomach and other types of cancers. Biosimilars can also be used to treat side effects of cancer treatments, such as low white blood cell counts, which increase the risk of infections.
Issues